S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

CymaBay Therapeutics Earnings Date, Estimates, & History

+0.08 (+2.61%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
280,563 shs
Average Volume
311,380 shs
Market Capitalization
$217.49 million
P/E Ratio
Dividend Yield

Earnings Summary

Earnings Date
Mar. 24

Actual EPS
(Nov. 10)
Missed By -$0.07

Consensus EPS
(Nov. 10)

Last Year's Q4 EPS

Skip Charts & View Estimated and Actual Earnings Data

CymaBay Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CymaBay Therapeutics Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

CymaBay Therapeutics (NASDAQ:CBAY) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.33)($0.33)($0.33)
Q2 20221($0.34)($0.34)($0.34)
Q3 20221($0.34)($0.34)($0.34)
Q4 20221($0.49)($0.49)($0.49)
FY 20224($1.50)($1.50)($1.50)

CBAY Earnings Information

CymaBay Therapeutics last announced its quarterly earnings results on November 10th, 2021. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.07. CymaBay Therapeutics has generated ($1.15) earnings per share over the last year (($1.15) diluted earnings per share). Earnings for CymaBay Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.34) per share. CymaBay Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 24th, 2022 based off prior year's report dates.

CymaBay Therapeutics (NASDAQ:CBAY) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
3/12/2020Q4 2019($0.39)($0.43)($0.04)($0.28)  
8/7/2019Q2 2019($0.37)($0.35)+$0.02($0.35)
2/28/2019Q4 2018($0.36)($0.32)+$0.04($0.32)
8/10/2018Q2 2018($0.25)($0.2910)($0.0410)($0.30)
5/9/2018Q1 2018($0.14)($0.32)($0.18)($0.32)$5.00 million
3/15/2018Q4 2017($0.17)($0.11)+$0.06($0.11)$1.25 million$5.20 million  
11/8/2017Q3 2017($0.19)($0.21)($0.02)($0.21)$9.50 million
8/10/2017Q2 2017($0.25)($0.31)($0.06)($0.31)
5/11/2017Q1 2017($0.2670)($0.20)+$0.0670($0.20)$4.79 million
3/23/2017Q4 2016($0.28)($0.30)($0.02)($0.30)
11/9/2016Q3 2016($0.31)($0.25)+$0.06($0.25)  
5/7/2015Q1 2015($0.43)($0.44)($0.01)($0.44)
(Earnings results data provided by Zacks Investment Research)

CymaBay Therapeutics (NASDAQ:CBAY) Earnings Frequently Asked Questions

When is CymaBay Therapeutics's earnings date?

CymaBay Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 24th, 2022 based off last year's report dates. Learn more on CBAY's earnings history

Did CymaBay Therapeutics beat their earnings estimates last quarter?

In the previous quarter, CymaBay Therapeutics (NASDAQ:CBAY) missed the analysts' consensus estimate of ($0.26) by $0.07 with a reported earnings per share (EPS) of ($0.33). Learn more on CBAY's earnings details

How can I listen to CymaBay Therapeutics's earnings conference call?

The conference call for CymaBay Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How much profit does CymaBay Therapeutics generate each year?

CymaBay Therapeutics (NASDAQ:CBAY) has a recorded net income of -$50.99 million. CBAY has generated -$1.15 earnings per share over the last four quarters.

What is CymaBay Therapeutics's EPS forecast for next year?

CymaBay Therapeutics's earnings are expected to decrease from ($1.13) per share to ($1.34) per share in the next year.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.